Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Individualised Homeopathy with Standard of Care (SOC): The administration of IHM once a day (OD) orally in centesimal potency (30/200/1M), as decided appropriate to the case, along with
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age > 18 years 2. Patients having moderate to severe Allergic Rhinitis as per ARIA guidelines 3. Atopic: reactive to inhaled allergens with positive skin test results 4. More than 1 year history of AR.
Exclusion criteria
Exclusion criteria: Any other types of chronic rhinitis History of anaphylactic reactions Moderate to severe atopic dermatitis Symptoms of asthma in accordance with the GINA criteria with more than one of the following: (1) occurrence of asthma symptoms more than twice per week, (2) any night waking due to asthma, (3) reliever (beta-2-sympathomimeticdrug) needed more than twice per week, except for reliever taken before exercise, (4) activity limitation due to asthma Renal insufficiency (serum creatinine concentration above (0.6â??1.4 mg/dl or 50â??130 μmol/l) measured within the last 16 weeks; Current daily use of topical or systemic corticosteroids; Allergen-specific immunotherapy used currently or within the past 3 years; Homeopathic therapy used currently or within the past 6 weeks; Recent (the past 6 weeks) use of other complementary and integrative medicine treatments for AR Alcohol addiction; pregnancy or breastfeeding; Serious acute or chronic organic diseases or serious mental disorder; Severely immuno-compromised patients for example patients with history of HIV infection, patients with solid organ transplantation or bone marrow transplantation, patients receiving chemotherapy/radiotherapy, patients with primary immunodeficiency. Have cardiovascular disease or severe haematological illness like Sickle cell disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total nasal symptom scores (TNSS)Timepoint: 0,2, 4, 8, and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Mini RQLQ (rhino-conjunctivitis quality of life questionnaire) VAS (Visual analog scale)Timepoint: 0,4,8, and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Ashish Kumar Dixit
AIIMS Bhopal
Outcome results
None listed